Factor V assay
Commercial- Indications
- Liver health monitoring
Company intelligence / Profile preview
LuminoDx has achieved CLIA certification for its San Diego laboratory and launched its first clinical diagnostic test—a Factor V assay for liver health. The company is preparing to add a predictive test for liver rejection post-transplant. Its proprietary biomarker-based liquid biopsy solutions are designed to optimize immunosuppression dosing and reduce comorbidities in post-transplant care. The company also offers services in Olink proteomics, extracellular vesicle analysis, and microRNA detection.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LuminoDx.